Effectiveness of Pamidronate Infusion in the Treatment of Charcot Arthropathy
https://doi.org/10.5704/MOJ.2403.009
- Author:
Bajuri MY
1
;
Md-Noorpi NH
1
;
Yin MK
2
;
Azman I
1
;
Adib-Adham NS
1
Author Information
1. Department of Orthopaedics and Traumatology, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
2. Department of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
- Publication Type:Journal Article
- Keywords:
charcot, arthropathy, pamidronate, bisphosphonates
- From:Malaysian Orthopaedic Journal
2024;18(No.1):66-72
- CountryMalaysia
- Language:English
-
Abstract:
Introduction: The objective of this case series is to
investigate the efficacy and safety of intravenous infusion of
Pamidronate, a second generation bisphosphonate, in the
treatment of active Charcot arthropathy.
Materials and methods: All patients with active Charcot
arthropathy treated at the medical centre from 1 January
2013 to 30 June 2020 were included in the study. Efficacy
outcome was evaluated based on time to consolidate findings
observed through radiographic examination, while safety
outcome was evaluated based on the incidence of adverse
event (AE) occurrence.
Results: A total of 81 patients (37 male, 44 female)
diagnosed with active Charcot arthropathy were included.
64.2% of patients were at stage 1 of Charcot arthropathy
whereas 35.8% were at stage 2. The mean time to
consolidate for stage 1 and stage 2 was 6.50 ± 4.21 months
and 3.63 ± 2.92 months respectively (p-value = 0.139). No
significant association was observed between gender,
ethnicity and disease stage with the consolidation time (pvalue >0.05). The rate of AE incidence was 2.5%, observed
in 2 patients who developed a fever during the treatment. No
other serious AE was observed in the study.
Conclusion: Intravenous Pamidronate infusion is a safe and
effective treatment option for Charcot arthropathy.
- Full text:202408071632249377616.2024my1353.pdf
